Antisense Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its produc… Read more
Market Cap & Net Worth: Antisense Therapeutics Limited (ATHJF)
Antisense Therapeutics Limited (PINK:ATHJF) has a market capitalization of $37.86 Million ($37.86 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #24133 globally and #8373 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Antisense Therapeutics Limited's stock price $0.04 by its total outstanding shares 901545024 (901.55 Million).
Antisense Therapeutics Limited Market Cap History: 2015 to 2024
Antisense Therapeutics Limited's market capitalization history from 2015 to 2024. Data shows change from $58.33 Million to $37.86 Million (-4.64% CAGR).
Antisense Therapeutics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Antisense Therapeutics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.76x
Antisense Therapeutics Limited's market cap is 12.76 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $58.33 Million | $3.86 Million | $706.92K | 15.10x | 82.51x |
| 2016 | $25.60 Million | $1.00 Million | -$2.51 Million | 25.60x | N/A |
| 2017 | $25.60 Million | $69.11K | -$2.75 Million | 370.45x | N/A |
| 2018 | $18.03 Million | $272.42K | -$2.33 Million | 66.19x | N/A |
| 2019 | $55.63 Million | $586.79K | -$2.94 Million | 94.80x | N/A |
| 2020 | $91.69 Million | $668.43K | -$5.91 Million | 137.17x | N/A |
| 2021 | $135.23 Million | $577.76K | -$8.06 Million | 234.06x | N/A |
| 2022 | $58.60 Million | $1.78 Million | -$5.81 Million | 32.96x | N/A |
| 2023 | $9.02 Million | $1.58 Million | -$11.38 Million | 5.71x | N/A |
| 2024 | $37.86 Million | $2.97 Million | -$11.92 Million | 12.76x | N/A |
Competitor Companies of ATHJF by Market Capitalization
Companies near Antisense Therapeutics Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Antisense Therapeutics Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Antisense Therapeutics Limited Historical Marketcap From 2015 to 2024
Between 2015 and today, Antisense Therapeutics Limited's market cap moved from $58.33 Million to $ 37.86 Million, with a yearly change of -4.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $37.86 Million | +320.00% |
| 2023 | $9.02 Million | -84.62% |
| 2022 | $58.60 Million | -56.67% |
| 2021 | $135.23 Million | +47.49% |
| 2020 | $91.69 Million | +64.83% |
| 2019 | $55.63 Million | +208.50% |
| 2018 | $18.03 Million | -29.58% |
| 2017 | $25.60 Million | 0.00% |
| 2016 | $25.60 Million | -56.11% |
| 2015 | $58.33 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 28th, 2025 the market cap of Antisense Therapeutics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.86 Million USD |
| MoneyControl | $37.86 Million USD |
| MarketWatch | $37.86 Million USD |
| marketcap.company | $37.86 Million USD |
| Reuters | $37.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.